STAT+: Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna

STAT NewsIndependentCenter5 days ago

This article features an exclusive interview with Kenneth Chien, a co-founder of Moderna, discussing the future of mRNA technology, particularly its potential in developing cancer vaccines. The piece highlights Chien's predictions about how mRNA could transform oncology and benefit broader medical fields. It references past achievements of Moderna, including partnerships with AstraZeneca and the development of mRNA vaccines during the pandemic. However, the article notes that some planned collaborations, such as the development of up to 40 mRNA-based therapies for cancer and cardiovascular diseases, did not come to fruition. The content is exclusive to STAT+ subscribers.

Bias read (Center): The article focuses on scientific and medical advancements rather than overtly political issues. While it discusses corporate developments within the biotech industry, there is no clear ideological leaning in the framing or emphasis. The narrative remains balanced, presenting both historical context